Article by Disease | Therapeutic Utilities of Pediatric Cardiac Catheterization


Bentham Cardiovascular Disorders Collection | Cardiovascular Disorders | Aortic Coarctation 

Therapeutic cardiac catheterization constantly evolves and widens its spectrum of usage in the pediatric population. The advent of sophisticated devices and well-designed equipment has made the management of many congenital cardiac lesions more efficient and safer, while providing more comfort to the patient.




Read out more at:

EDITOR’S CHOICE ARTICLE – Current Concepts and Perspectives on Connexin43: A Mini Review

Journal Name: Current Protein & Peptide Science

Author(s): Qingwei Zhang, Xiao Bai, Yang Liu, Kai Wang, Baozhong Shen*, Xilin Sun*




Graphical Abstract:



Connexins are a family of gap junction proteins widely distributed in human organs and tissues. Gap junctions are organized systems of intercellular protein channels that allow the exchange of ions, chemical signals, and energy substrates between two adjacent cells. Connexin43 (Cx43) is the most abundant isoform of connexins in the heart which play an important role in myocardium disease. Numerous studies have shown that Cx43 was involved in tumor migration and invasion by mediating gap junctions between tumor cells and normal cells. Changes in the expression and distribution of Cx43 contribute to heart disease and cancer. This review discusses current knowledge on the functional and structural abnormalities in Cx43 associated with heart disease and cancer, aiming to highlight the importance of this connexin as an emerging therapeutic target. Here, the current knowledge on the pharmacology of Gap Junction Channels and Hemichannels were also summarized. Finally, we propose that these knowledges can be exploited to identify new diagnostic and effective therapeutic approaches for ischemic heart disease and cancer.


Fore more details, please visit:

Thought of the Day!


World Heart Day – Inforgraphics

Celebrate ‘World Heart Day’ with Bentham Science Publishers! Learn All You Need To Know About Protecting Your Heart Through This Inforgraphics:

heart day

To access journals on Cardiology:
To access eBooks on Cardiology:

#WorldHeartDay #Heart #cardiovascular #cardiology


Source: World Heart Association

First Stroke Guidelines for Women Created

The American Heart Association outlined Thursday its first ever guidelines for primary care provider sand OBGYNs developed specifically to prevent women’s strokes, the third leading cause of death for U.S. women, and the fifth leading cause for men.

Stroke risk factors for both men and women include high blood pressure, high cholesterol, and smoking, but certain hormonal changes can reportedly increase a woman’s risk.

“If you are a woman…your risk is also influenced by hormones, reproductive health, pregnancy, childbirth and other sex-related factors,” said Cheryl Bushnell, M.D., M.H.S., author of the new scientific statement published in the American Heart Association journal Stroke.

According to the guidelines, women with a history of high blood pressure before pregnancy are at risk for preeclampsia, a blood pressure disorder that occurs during pregnancy. Preeclampsia doubles the risk for stroke and increases the risk for high blood pressure four-fold, according to the guidelines.

The combination of high blood pressure and birth control use can also raise a woman’s risk for stroke. Migraines with aura, diabetes, depression, and emotional stress, which occur more frequently among women, are also

Read more: American Heart Association Notes Women’s Stroke Risk Factors |

New Blood Thinner Promises Less Bleeding Risk

An experimental drug appears to prevent dangerous blood clots, without raising the risk of excessive bleeding — at least in animals. 

ImageScientists found that an injectable antibody protected rabbits from developing blood clots but didn’t cause bleeding complications — a potential side effect of all current anti-clotting drugs.
The findings, reported Feb. 5 in the journal Science Translational Medicine, are only an initial step.
The hope is to eventually bring safer clot-preventing drugs to the market, said researcher Dr. Thomas Renne, of the Karolinska Institute in Stockholm, Sweden.
Renne said his team plans to test the antibody, dubbed 3F7, in a phase I study — a small trial that tests the safety of a drug in humans.
An expert not involved in the research said these early findings “are really quite exciting.”
“The holy grail in this field is to be able to give something that prevents clots, without causing bleeding,” said Dr. Alvin Schmaier, a professor at Case Western Reserve University in Cleveland, who wrote an editorial published with the study.
Right now, anti-clotting drugs are given for a number of reasons. Doctors use them, for example, when surgery patients or critically ill newborns have to be hooked up to a heart-lung machine — a scenario, Renne noted, that would instantly cause blood clots if not for the medications.
In those cases, an IV drug called heparin has long been the choice for preventing clots, but it carries the risk of potentially dangerous, or even fatal, internal bleeding.
Another problem with heparin, Schmaier said, is that it’s messy to make. It’s isolated from pig intestines, and pig farmers in China supply much of the world’s heparin. Several years ago, tainted heparin batches from China were tied to an outbreak of severe allergic reactions and more than 80 deaths in the United States alone.
Schmaier said an alternative drug that could be manufactured under strict quality control is needed.
Renne’s team developed the new antibody based on research into a blood protein called factor XII. Factor XII is involved in the process of blood clotting, but experts have long known that people who lack the protein — about one in every one million people — do not have any special risk of bleeding.
So Renne, who is also affiliated with the University Hospital Hamburg-Eppendorf in Germany, and his colleagues studied mice that were engineered to lack factor XII. They found that the animals could not develop blood clots, but — like their human counterparts — did not suffer from bleeding. From there, the researchers developed the 3F7 antibody to block factor XII activity.
The antibody effectively blocked clot formation in rabbits that were placed on a simulation of a heart-lung device. It worked about as well as heparin, the researchers found, but without causing bleeding.
Human studies are still needed, but the researchers already know the antibody blocks factor XII in human blood.
“I think that blocking this target (factor XII) is going to prove very useful in procedures where people have to be hooked up to a machine,” Schmaier said.
Anti-clotting drugs are commonly used outside of hospitals, too. Many people take oral medications, such as warfarin (Coumadin), to prevent clots that could lead to a heart attack or stroke. Among these are patients with the heart-rhythm disorder atrial fibrillation and those with artificial heart valves.
Since 3F7 is an antibody, it would have to be injected, Renne explained. So, if it pans out, it could be an alternative to the heparin used in hospitals, but it wouldn’t replace the oral medications people use long-term.
However, Renne said, drug companies are looking for oral agents that block factor XII. 

“That is a longer-term goal,” he said.

Schmaier said he expects to see a lot more work aimed at factor XII. “I think this report is the tip of the iceberg,” he said.
Several of Renne’s co-researchers are employees of the pharmaceutical company CSL, which is developing the 3F7 antibody. Renne is named as inventor on a patent application covering the use of factor XII as a target of anti-clotting drugs.

Read Latest Breaking News from 

%d bloggers like this: